Department of Dermatology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Institute for Medical Microbiology, Immunology and Hygiene (IMMIH), Center for Molecular Medicine Cologne (CMMC), CECAD, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Cell Oncol (Dordr). 2019 Jun;42(3):319-329. doi: 10.1007/s13402-019-00427-1. Epub 2019 Feb 18.
The X-linked inhibitor of apoptosis (XIAP) is a potent cellular inhibitor of apoptosis, based on its unique capability to bind and to inhibit caspases. However, XIAP is also involved in a number of additional cellular activities independent of its caspase inhibitory function. The aim of this study was to investigate whether modulation of XIAP expression affects apoptosis-independent functions of XIAP in melanoma cells, restores their sensitivity to apoptosis and/or affects their invasive and metastatic capacities.
XIAP protein levels were analyzed by immunohistochemical staining of human tissues and by Western blotting of melanoma cell lysates. The effects of pharmacological inhibition or of XIAP down-regulation were investigated using ex-vivo and transwell invasion assays. The biological effects of XIAP down-regulation on melanoma cells were analyzed in vitro using BrdU/PI, nucleosome quantification, adhesion and migration assays. In addition, new XIAP binding partners were identified by co-immunoprecipitation followed by mass spectrometry.
Here we found that the expression of XIAP is increased in metastatic melanomas and in invasive melanoma-derived cell lines. We also found that the bivalent IAP antagonist birinapant significantly reduced the invasive capability of melanoma cells. This reduction could be reproduced by downregulating XIAP in melanoma cells. Furthermore, we found that the migration of melanoma cells and the formation of focal adhesions at cellular borders on fibronectin-coated surfaces were significantly reduced upon XIAP knockdown. This reduction may depend on an altered vimentin-XIAP association, since we identified vimentin as a new binding partner of XIAP. As a corollary of these molecular alterations, we found that XIAP down-regulation in melanoma cells led to a significant decrease in invasion of dermal skin equivalents.
From our data we conclude that XIAP acts as a multifunctional pro-metastatic protein in skin melanomas and, as a consequence, that XIAP may serve as a therapeutic target for these melanomas.
X 连锁凋亡抑制蛋白(XIAP)是一种强有力的细胞凋亡抑制剂,基于其结合和抑制半胱天冬酶的独特能力。然而,XIAP 还参与了许多与其半胱天冬酶抑制功能无关的其他细胞活动。本研究旨在探讨调节 XIAP 表达是否会影响黑色素瘤细胞中 XIAP 的凋亡非依赖性功能,恢复其对凋亡的敏感性,以及影响其侵袭和转移能力。
用人组织的免疫组织化学染色和黑色素瘤细胞裂解物的 Western 印迹分析 XIAP 蛋白水平。使用体外和 Transwell 侵袭测定法研究药物抑制或 XIAP 下调的影响。通过 BrdU/PI、核小体定量、黏附和迁移测定法在体外分析 XIAP 下调对黑色素瘤细胞的生物学影响。此外,通过免疫沉淀结合质谱鉴定了新的 XIAP 结合伴侣。
我们发现 XIAP 的表达在转移性黑色素瘤和侵袭性黑色素瘤衍生细胞系中增加。我们还发现双价 IAP 拮抗剂 birinapant 显著降低了黑色素瘤细胞的侵袭能力。这一减少可以通过下调黑色素瘤细胞中的 XIAP 来重现。此外,我们发现黑色素瘤细胞的迁移和在纤维连接蛋白包被表面上细胞边界处形成的焦点粘附明显减少。这种减少可能取决于一种改变的波形蛋白-XIAP 关联,因为我们发现波形蛋白是 XIAP 的一个新的结合伴侣。作为这些分子改变的必然结果,我们发现 XIAP 下调导致黑色素瘤细胞真皮皮肤等效物的侵袭性显著降低。
从我们的数据中,我们得出结论,XIAP 在皮肤黑色素瘤中作为一种多功能的促转移蛋白发挥作用,因此,XIAP 可能成为这些黑色素瘤的治疗靶点。